Crossmark

Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion

Crossref DOI link: https://doi.org/10.1007/s10549-026-07906-8

Published Online: 2026-02-05

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Tae Hoon https://orcid.org/0000-0002-4723-3931
Lee, Hyunwoo https://orcid.org/0000-0001-7513-2882
Jang, Jeong Yun https://orcid.org/0000-0002-3167-0635
Park, Won https://orcid.org/0000-0003-4686-2071
Cho, Won Kyung https://orcid.org/0000-0002-4736-8270
Cho, Eun Yoon https://orcid.org/0000-0003-4675-4492
Ahn, Jin Seok https://orcid.org/0000-0002-2880-6730
Park, Yeon Hee https://orcid.org/0000-0003-4156-9212
Nam, Seok Jin https://orcid.org/0000-0003-1072-8954
Kim, Seok Won https://orcid.org/0000-0002-6130-7570
Lee, Jeong Eon https://orcid.org/0000-0003-0037-2456
Kim, Haeyoung https://orcid.org/0000-0003-1808-7573
Funding

Funding for this research was provided by:

National Research Foundation of Korea (RS-2023-00252283)

Samsung Medical Center, Sungkyunkwan University (SMO1240501)

Sungkyunkwan University
License Information

Text and Data Mining valid from 2026-02-01

Version of Record valid from 2026-02-05
More Information

Article History

Received: 9 September 2025

Accepted: 27 January 2026

First Online: 5 February 2026

Declarations

:

: The authors declare no competing interests.

: The requirement for informed consent was waived due to the retrospective nature of the study.

: The study was approved by the Institutional Review Board of Samsung Medical Center (approval number 2024-02-110).

Document is current

Any future updates will be listed below